News

The company said that due to its safety profile, the use of Lemtrada should be reserved for patients who have had an inadequate response to two or more

The new 30,000m² facility, to be built on the grounds of the company’s existing bulk pharmaceutical manufacturing plant, will house six 15,000l bioreactors, purification area as well as

Around £4m has been set aside by GSK as initial funding round, which will support successful proposals from researchers in Côte d’Ivoire, Cameroon, Ghana, the Gambia, Nigeria, Kenya,

The company sNDA has been granted priority review status by the FDA and it was based on the results of a three-week monotherapy trial in 403 pediatric patients,

As per the auction process, Aurobindo emerged as best bidder with a bid of $132.5m to acquire the assets of Natrol with an agreement to take on certain

The Notice of Allowance is for U.S. Patent Application No. 14/230,067, "Methods for Treatment of Attention Deficit Hyperactivity Disorder", which relates to HLD-200, including its unique pharmacokinetic profile.

This award enables Integral Molecular to understand how human antibodies protect (or fail to protect) against these viruses. Using its proprietary Shotgun Mutagenesis Epitope Mapping technology, Integral Molecular

MEDI2452 is being developed by MedImmune, AstraZeneca’s biologics research and development arm. Updates on BRILINTA development programme and data from cardiovascular portfolio to be presented at American Heart

"RMD’s world-class research continues to be on the cutting edge of new technologies," said Peter Sulick, Dynasil’s Chairman of the Board, Chief Executive Officer and President. "RMD is